Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.97
BUR's Cash to Debt is ranked lower than
82% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 83.29 vs. BUR: 0.97 )
Ranked among companies with meaningful Cash to Debt only.
BUR' s Cash to Debt Range Over the Past 10 Years
Min: 0.97  Med: No Debt Max: No Debt
Current: 0.97
Equity to Asset 0.36
BUR's Equity to Asset is ranked lower than
80% of the 711 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BUR: 0.36 )
Ranked among companies with meaningful Equity to Asset only.
BUR' s Equity to Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.89 Max: 0.94
Current: 0.36
0.36
0.94
F-Score: 3
Z-Score: -11.48
M-Score: -7.18
WACC vs ROIC
21.15%
-370.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -5941.51
BUR's Operating margin (%) is ranked lower than
90% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -81.51 vs. BUR: -5941.51 )
Ranked among companies with meaningful Operating margin (%) only.
BUR' s Operating margin (%) Range Over the Past 10 Years
Min: -18770  Med: -6571.53 Max: -5941.51
Current: -5941.51
-18770
-5941.51
Net-margin (%) -5946.23
BUR's Net-margin (%) is ranked lower than
91% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. BUR: -5946.23 )
Ranked among companies with meaningful Net-margin (%) only.
BUR' s Net-margin (%) Range Over the Past 10 Years
Min: -18486.67  Med: -6270.75 Max: -5946.23
Current: -5946.23
-18486.67
-5946.23
ROE (%) -158.97
BUR's ROE (%) is ranked lower than
89% of the 875 Companies
in the Global Biotechnology industry.

( Industry Median: -32.93 vs. BUR: -158.97 )
Ranked among companies with meaningful ROE (%) only.
BUR' s ROE (%) Range Over the Past 10 Years
Min: -158.97  Med: -66.3 Max: -53.49
Current: -158.97
-158.97
-53.49
ROA (%) -119.40
BUR's ROA (%) is ranked lower than
89% of the 967 Companies
in the Global Biotechnology industry.

( Industry Median: -29.03 vs. BUR: -119.40 )
Ranked among companies with meaningful ROA (%) only.
BUR' s ROA (%) Range Over the Past 10 Years
Min: -119.4  Med: -63.24 Max: -48.16
Current: -119.4
-119.4
-48.16
ROC (Joel Greenblatt) (%) -1139.96
BUR's ROC (Joel Greenblatt) (%) is ranked lower than
64% of the 927 Companies
in the Global Biotechnology industry.

( Industry Median: -368.19 vs. BUR: -1139.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BUR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1207.15  Med: -961.88 Max: -398.4
Current: -1139.96
-1207.15
-398.4
Revenue Growth (3Y)(%) 44.20
BUR's Revenue Growth (3Y)(%) is ranked higher than
88% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. BUR: 44.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BUR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 44.2
Current: 44.2
0
44.2
EBITDA Growth (3Y)(%) 1.40
BUR's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. BUR: 1.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BUR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -16.4  Med: 1.3 Max: 259.3
Current: 1.4
-16.4
259.3
EPS Growth (3Y)(%) 0.40
BUR's EPS Growth (3Y)(%) is ranked higher than
55% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. BUR: 0.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BUR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.1  Med: 0.4 Max: 323.6
Current: 0.4
-18.1
323.6
» BUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

BUR Guru Trades in

Q2 2014

BUR Guru Trades in Q2 2014

Chuck Royce 433,253 sh (+3.18%)
» More
Q3 2014

BUR Guru Trades in Q3 2014

Chuck Royce 419,903 sh (-3.08%)
» More
Q4 2014

BUR Guru Trades in Q4 2014

Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:RCAR, NAS:CALA, NAS:CATB, AMEX:CRMD, OTCPK:CWBR, OTCPK:CNBX, NAS:AGLE, NAS:DRNA, OTCPK:NURPF, NAS:ALDX, NAS:CAPR, NAS:ANTH, NAS:PPHM, NAS:LIFE, NAS:SBPH, NAS:PIRS, NAS:TRIL, NAS:AFMD, NAS:NEPT, NAS:ADMA » details
Traded in other countries:BU.Canada, BNE.Germany,
Burcon NutraScience Corp and its subsidiary are research and development companies that are developing plant protein extraction and purification technology in the field of functional, renewable plant proteins.

Burcon NutraScience Corp was incorporated on November 3, 1998. The Company, through its subsidiary, Burcon NutraScience (MB) Corp. is a research and development company building a portfolio of composition, application and process patents around its plant protein extraction and purification technology. The Company's products include CLARISOY, a soy protein isolate, which is used in various food products, including protein shakes, power bars, soups and sauces, meats and meat analogs, and breads and baked foods; and PEAZAZZ, a soluble pea protein isolate. Its products also comprise canola protein isolates, such as Supertein that comprises albumin proteins used in beverages, confectionery, aerated desserts, and protein bars; Puratein, which consists of globulin proteins used in dressings and sauces, meat substitutes, baked goods, and protein bars.

Ratios

vs
industry
vs
history
Forward P/E 35.46
BUR's Forward P/E is ranked lower than
99.99% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 19.92 vs. BUR: 35.46 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 76.12
BUR's P/B is ranked lower than
99% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: 3.57 vs. BUR: 76.12 )
Ranked among companies with meaningful P/B only.
BUR' s P/B Range Over the Past 10 Years
Min: 7.95  Med: 16.16 Max: 86.58
Current: 76.12
7.95
86.58
P/S 723.02
BUR's P/S is ranked lower than
93% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 12.03 vs. BUR: 723.02 )
Ranked among companies with meaningful P/S only.
BUR' s P/S Range Over the Past 10 Years
Min: 460  Med: 757.5 Max: 3540
Current: 723.02
460
3540
Current Ratio 0.82
BUR's Current Ratio is ranked lower than
90% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. BUR: 0.82 )
Ranked among companies with meaningful Current Ratio only.
BUR' s Current Ratio Range Over the Past 10 Years
Min: 0.82  Med: 10.12 Max: 55.01
Current: 0.82
0.82
55.01
Quick Ratio 0.82
BUR's Quick Ratio is ranked lower than
87% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. BUR: 0.82 )
Ranked among companies with meaningful Quick Ratio only.
BUR' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 10.12 Max: 55.01
Current: 0.82
0.82
55.01
Days Sales Outstanding 454.53
BUR's Days Sales Outstanding is ranked lower than
97% of the 595 Companies
in the Global Biotechnology industry.

( Industry Median: 63.02 vs. BUR: 454.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
BUR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 425.83  Med: 515.46 Max: 541.74
Current: 454.53
425.83
541.74

Buy Back

vs
industry
vs
history
Yield on cost (5-Year) 0.60
BUR's Yield on cost (5-Year) is ranked lower than
81% of the 285 Companies
in the Global Biotechnology industry.

( Industry Median: 1.75 vs. BUR: 0.60 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BUR' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 0.6
3-Year Average Share Buyback Ratio -3.90
BUR's 3-Year Average Share Buyback Ratio is ranked higher than
75% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. BUR: -3.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BUR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -75.5  Med: -5.7 Max: -2
Current: -3.9
-75.5
-2

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.96
BUR's Price/Median PS Value is ranked higher than
59% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. BUR: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
BUR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.67  Med: 1.05 Max: 3.95
Current: 0.96
0.67
3.95
Earnings Yield (Greenblatt) (%) -5.97
BUR's Earnings Yield (Greenblatt) (%) is ranked higher than
55% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: -8.00 vs. BUR: -5.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BUR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -11.1  Med: 0 Max: 0
Current: -5.97
-11.1
0

More Statistics

Revenue (TTM) (Mil) $0.08
EPS (TTM) $ -0.13
Beta1.16
Short Percentage of Float0.15%
52-Week Range $1.21 - 3.96
Shares Outstanding (Mil)35.83

Analyst Estimate

Mar17 Mar18
Revenue (Mil $) 2 9
EPS ($) -0.08 0.06
EPS w/o NRI ($) -0.08 0.06
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for BUR

Headlines

Articles On GuruFocus.com
Burelle: A Growing Euro for 50 cents Mar 12 2013 

More From Other Websites
BURCON ANNOUNCES COMPLETION OF OVER-SUBSCRIBED RIGHTS OFFERING Dec 01 2016
Burcon Announces Completion of Over-Subscribed Rights Offering Dec 01 2016
Burcon NutraScience Corp. :BUR-US: Earnings Analysis: Q2, 2017 By the Numbers : November 29, 2016 Nov 29 2016
Burcon reports 2Q loss Nov 14 2016
Burcon reports 2Q loss Nov 14 2016
FIRST LARGE-SCALE CLARISOY™ PRODUCTION FACILITY FULLY COMMISSIONED Nov 08 2016
First Large-Scale CLARISOY™ Production Facility Fully Commissioned Nov 08 2016
Burcon Announces Rights Offering Oct 24 2016
ETF’s with exposure to Burcon NutraScience Corp. : October 17, 2016 Oct 17 2016
ETF’s with exposure to Burcon NutraScience Corp. : October 5, 2016 Oct 05 2016
Burcon NutraScience Corp. :BUR-US: Earnings Analysis: Q1, 2017 By the Numbers : October 4, 2016 Oct 04 2016
Burcon Announces Results of Election of Board of Directors Sep 09 2016
FIRST LARGE-SCALE CLARISOY™ PRODUCTION FACILITY SCHEDULED TO BE COMMISSIONED IN FOURTH QUARTER Sep 06 2016
First Large-Scale CLARISOY™ Production Facility Scheduled to be Commissioned in Fourth Quarter Sep 06 2016
The Zacks Analyst Blog Highlights: Hershey's, Coach, Sysco, Burcon Nutrascience and Barfresh Food... Aug 12 2016
Consumer Stock Earnings Around the Corner: SYY, BUR, BRFH Aug 11 2016
Burford Capital Ltd. :BUR-GB: Earnings Analysis: For the six months ended June 30, 2016 : August 8,... Aug 08 2016
BURCON NUTRASCIENCE CORP Financials Aug 02 2016
Burcon NutraScience Corp. :BUR-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 Jul 26 2016
Burcon NutraScience Corp. :BUR-US: Earnings Analysis: Q4, 2016 By the Numbers : July 8, 2016 Jul 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)